KLOW peptide stack

GLOW plus KPV: GHK-Cu + BPC-157 + TB-500 + KPV, usually as one injectable vial

By MoveWell Research Team Updated November 1, 2026
KLOWGHK-Cucopper peptide+BPC-15715 amino acids+TB-500Tβ4 fragment+KPVshort peptideNo study has tested these four togetherKLOWGHK-Cucopper peptide+BPC-15715 amino acids+TB-500Tβ4 fragment+KPVshort peptideNo study has tested these four together
Evidence1/5No study of the blend, in people or animals
StatusNo legal way to buy it. Blends are excluded from the Oct 2026 HHS policy, GHK-Cu is not on it, and KPV is covered only on the skin or by mouth, not by injection.
LatestOctober 28, 2026: HHS said it won't act against licensed pharmacies that compound six single peptides, including BPC-157, TB-500 and KPV. Blends are excluded.1, 2

KLOW is GLOW with a fourth peptide, KPV, added for inflammation. No study has tested the blend.3 Injected KPV falls outside even the single-ingredient HHS policy, which covers KPV only on the skin or by mouth.2 Everything said about GLOW applies here, plus one more untested ingredient.

Other stacksGLOWWolverineGHK-Cu + microneedlingGHK-Cu + red lightAll stacks
In this guide
  1. Status and summary
  2. Ingredients
  3. What it's claimed to do
  4. Evidence: blend vs parts
  5. What users report
  6. Risks and legal status
  7. Safer alternatives
  8. Where to get it
  9. FAQ
  10. References

Ingredients

Each card shows the evidence for that peptide on its own, from its MoveWell guide.

Copper peptideGHK-Cu2/5Injected: animal and lab data only. Topical skin use rates 3/5.Read the guide Gastric peptide fragmentBPC-1572/5Almost all animal data. 5 small human studies, none with a clear benefit.Read the guide Thymosin β4 fragment, not Tβ4TB-5002/5Animal and lab data only. FDA found no study giving TB-500 to people.4Read the guide α-MSH fragmentKPV2/5Mouse and cell studies only. FDA found no human study of KPV.5Read the guide

Scale: 5 FDA-approved, 4 strong human, 3 limited human, 2 animal or lab only, 1 anecdotal. TB-500 is not thymosin β4 (Tβ4); Tβ4 trials don't count toward its grade.4

What it's claimed to do

KLOW is sold as GLOW's skin-and-repair pitch plus an anti-inflammatory peptide. KPV is a short peptide.3 It is the last three amino acids of α-MSH, a hormone that also calms inflammation.6

  • Everything claimed for GLOW: skin, scars, tendons, recovery
  • Calmer inflammation, including gut and skin

Doses and ratios vary by seller.3

Evidence: the blend vs each part alone

WhatWhat's been testedBest findingGrade
KLOW (all four)Nothing3None1/5
GLOW (three)NothingNone1/5
BPC-157 + TB-5001 rat study (n=32)7No added benefit over either alone2/5
GHK-Cu, injectedRats and cells; no human study of any injected doseRat ACL benefit gone by 12 weeks (not re-verified for this update)82/5
BPC-157Mostly rats; 5 small human studies9None with a clear benefit; none tested injection under the skin92/5
TB-500Rats and lab only; no human study of TB-5004Only group with a significant tendon-strength gain in the rat study72/5
KPVMice and cells; no human study of KPV5Reduced chemically induced colitis in mice2/5

FDA's own staff recommended against adding BPC-157 and TB-500 to the compounding list.10, 11 Its staff also recommended against KPV, citing no human data.5 The advisory panel voted 8–6, with one abstention, in favor of each of the three.10 Those votes judged each peptide alone. None considered a blend.

The one combination test, BPC-157 with TB-500 in rats, found the pair "did not confer additional benefits compared to either agent alone".7

What users report

AnecdotalFrom Reddit threads, not research. Small sample.12, 13, 14

Reported benefits

  • One poster reported better skin, a resolved shoulder pain and a large jump in training volume after a month. A few others take it daily for recovery and skin and report no outcome yet.
  • In GHK-Cu threads, a few describe KLOW as gentler to inject than GHK-Cu alone.

Skepticism

  • Several commenters doubted that a peptide blend could double training capacity, and many pointed to the poster's long supplement list.

Comments are paraphrased. We leave out doses. A Reddit claim that BPC-157 and KPV act as "mast-cell stabilizers" came with no source.

Safer or evidence-based alternatives

  • For skin: topical GHK-Cu, with one small randomized trial behind it.21 See the GHK-Cu guide.
  • For tendon pain: structured exercise, which no add-on has convincingly beaten in 68 randomized trials.22
  • For inflammation or gut symptoms: see a clinician. KPV under the HHS policy is limited to creams or oral forms from a licensed pharmacy, with a prescription.2

Where to get it

There is no legal source for KLOW. We don't list sellers of blends or research-use vials.

Single-ingredient options: GHK-Cu, BPC-157, TB-500 and KPV.

FAQ

What does KPV add to GLOW?

In theory, an anti-inflammatory effect. It has never been tested in the blend, and on its own it has only mouse and cell data. See our KPV guide.

Is KLOW legal?

No licensed pharmacy can make it. Blends are excluded from the HHS policy, GHK-Cu is not on it, and KPV is covered only on the skin or by mouth.

Is KLOW gentler than GHK-Cu?

Some users say so. There is no study.

Can athletes use KLOW?

No. It contains BPC-157 and TB-500, both prohibited at all times by WADA.

References

22 sources, with links
  1. HHS. Notice of availability: 503A enforcement discretion policy for certain peptide bulk drug substances. Federal Register public inspection, FR Doc. 2026-22192; Docket HHS-OASH-2026-0496 (Oct 28, 2026; publication scheduled Oct 30). PDF
  2. HHS. 503A peptide enforcement discretion policy, Appendix B (forms, routes and conditions). hhs.gov
  3. Superpower. GLOW peptide guide (a telehealth seller's guide; used only for its statements that no study of the blend exists, that none tested KPV alongside the other peptides, that KPV is a short peptide, and that doses vary by seller). Link
  4. FDA. Review memo: TB-500-related bulk drug substances (May 15, 2026). Pharmacy Compounding Advisory Committee, Jul 23–24, 2026. States that thymosin beta-4 and TB-500 "are not the same substance" and that no articles were found in which TB-500 was given to humans. fda.gov
  5. FDA. Briefing document: KPV-related bulk drug substances (review dated May 12, 2026). Pharmacy Compounding Advisory Committee, Jul 23–24, 2026. fda.gov
  6. Luger TA, Scholzen TE, Brzoska T, Böhm M. New insights into the functions of alpha-MSH and related peptides in the immune system. Ann N Y Acad Sci 2003;994:133–140. PubMed
  7. Biçer O et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats. Joint Dis Relat Surg 2026;37(3):822–837. DOI 10.52312/jdrs.2026.2951
  8. Fu SC et al. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction. J Orthop Res 2015. DOI 10.1002/jor.22831
  9. FDA. Briefing document: BPC-157-related bulk drug substances. Pharmacy Compounding Advisory Committee, Jul 23–24, 2026. fda.gov
  10. McDermott Will & Schulte. Bulk-list bound: PCAC backs majority of peptides in two-day public meeting (Jul 2026). Vote counts; FDA had posted no minutes when checked. Link
  11. Hyman Phelps, FDA Law Blog. Peptide-l wave: PCAC approves four bulk drug substances for the 503A list (Jul 2026). Secondary report of the TB-500 discussion at the meeting. Link
  12. Reddit, r/Biohackers. "After a month on [KLOW], I'm questioning my supplement stack" (about Aug 2025; 56 of 181 comments captured). Thread
  13. Reddit, r/Biohackers. "Introducing new peptides 1 by 1 or just run KLOW?" (about Feb 2026). Thread
  14. Reddit, r/Biohacking. "GHKCU" (about Dec 2025; KLOW described as milder). Thread
  15. ArentFox Schiff. RUO-ined: five peptide vendors learn "research use only" is not a legal strategy (Aug 2026). Link
  16. FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of Apr 22, 2026). fda.gov
  17. World Anti-Doping Agency. 2026 Prohibited List: S0 names BPC-157; S2.3 names "Thymosin-ß4 and its derivatives e.g. TB-500"; both prohibited at all times. KPV and GHK-Cu are not named (copy hosted by SEGAS). PDF
  18. FDA. Bulk drug substances nominated for use in compounding under 503A, categories list (updated May 14, 2026). Entry: "GHK-Cu (except for injectable routes of administration)." fda.gov
  19. BakerHostetler. HHS issues enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances (Oct 2026). Link
  20. Hyman Phelps, FDA Law Blog. HHS peptide enforcement discretion policy (Oct 28, 2026). Link
  21. Badenhorst T et al. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci 2016;4:166. DOI 10.4172/2329-8847.1000166
  22. Challoumas D, Crosbie G, O'Neill S, Pedret C, Millar NL. Effectiveness of exercise treatments with or without adjuncts for common lower limb tendinopathies: a living systematic review and network meta-analysis. Sports Med Open 9:71 (68 RCTs). Repository copy

This page is for education and is not medical advice. None of these peptides is FDA-approved. Talk to a clinician before using any peptide, especially by injection.